title: Access to HAART in HIV-infected immigrants: a retrospective multicenter Italian study.
abstract: Since 1996, AIDS has declined in the Italian population, but cases in foreign patients, including both recent immigrants and long-term residents, have increased from 3.9% in 1995-1996 to 15.4% in 2001-2002. This increase can only be partly explained by a higher migratory flow and might reflect a delayed access to health facilities and to antiretroviral therapy in migrants. We performed a survey for the year 2003 of HIV-infected immigrants to Italy from countries outside the European Union to verify which factors might influence a lack of access to highly active antiretroviral therapy (HAART). Italian centers of infectious diseases were requested to send sociodemographic and clinical data of HIV-infected immigrant patients. A total of 553 HIV-infected immigrants (49.9% women) were evaluated, representing 6.5% of all HIV-infected patients from these centers. The mean duration of residency in Italy was 6.6 +/- 5.0 years. The country of origin was Africa (64.5%), North and South America (24.2%), Eastern Europe (7.0%), and Asia (3.8%). A total of 407 of 553 patients (73.6%) were taking antiretroviral drugs at the time of screening. Females presented a younger age (p = 0.001), a lower frequency of Centers for Disease Control (CDC) stage B/C (p = 0.008) and a more frequent heterosexual exposure to HIV (p < 0.001), while no differences were observed for time of first positive serology (p = 0.7). CD4 cell count (p = 0.9) and log plasma HIV-RNA (p = 0.1). Characteristics of HAART patients were compared to those of nontreated patients, despite a CD4 cell count less than 350 cells/mm(3). No significant difference was found for gender, country of origin, risk factor, and years of Italian residence, while legal immigrants (p = 0.018) and registered in the National Health Service (p = 0.014) were significantly more likely to receive HAART compared to illegal immigrants.
authors.affiliation: Clinic of Infectious Diseases, University of Foggia, v.le L Pinto, 1-71100 Foggia, Italy. a.saracino@medicina.unifg.it
authors.forename: A
authors.initials: A
authors.lastname: Saracino
authors.forename: I
authors.initials: I
authors.lastname: El-Hamad
authors.forename: R
authors.initials: R
authors.lastname: Prato
authors.forename: D C
authors.initials: DC
authors.lastname: Cibelli
authors.forename: A
authors.initials: A
authors.lastname: Tartaglia
authors.forename: E
authors.initials: E
authors.lastname: Palumbo
authors.forename: M C
authors.initials: MC
authors.lastname: Pezzoli
authors.forename: G
authors.initials: G
authors.lastname: Angarano
authors.forename: G
authors.initials: G
authors.lastname: Scotto
mesh_terms: D000328:Adult; D023241:Antiretroviral Therapy, Highly Active; D018791:CD4 Lymphocyte Count; D004641:Emigration and Immigration / Q000706:statistics & numerical data*; D005260:Female; D015658:HIV Infections / Q000188:drug therapy* / Q000209:etiology; D006297:Health Services Accessibility; D006801:Humans; D007558:Italy; D008297:Male; D015337:Multicenter Studies as Topic; D012189:Retrospective Studies